- Home
- USAU vs TPST Comparison
USAU vs TPST Comparison
Compare USAU & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USAU
- TPST
- Stock Information
- Founded
- USAU N/A
- TPST 2011
- Country
- USAU United States
- TPST United States
- Employees
- USAU N/A
- TPST N/A
- Industry
- USAU Precious Metals
- TPST Biotechnology: Pharmaceutical Preparations
- Sector
- USAU Basic Materials
- TPST Health Care
- Exchange
- USAU Nasdaq
- TPST Nasdaq
- Market Cap
- USAU 59.6M
- TPST 33.8M
- IPO Year
- USAU N/A
- TPST N/A
- Fundamental
- Price
- USAU $6.00
- TPST $1.15
- Analyst Decision
- USAU Strong Buy
- TPST Strong Buy
- Analyst Count
- USAU 1
- TPST 4
- Target Price
- USAU $11.00
- TPST $20.75
- AVG Volume (30 Days)
- USAU 81.1K
- TPST 6.2M
- Earning Date
- USAU 12-13-2024
- TPST 11-06-2024
- Dividend Yield
- USAU N/A
- TPST N/A
- EPS Growth
- USAU N/A
- TPST N/A
- EPS
- USAU N/A
- TPST N/A
- Revenue
- USAU N/A
- TPST N/A
- Revenue This Year
- USAU N/A
- TPST N/A
- Revenue Next Year
- USAU N/A
- TPST N/A
- P/E Ratio
- USAU N/A
- TPST N/A
- Revenue Growth
- USAU N/A
- TPST N/A
- 52 Week Low
- USAU $3.05
- TPST $0.92
- 52 Week High
- USAU $7.06
- TPST $6.76
- Technical
- Relative Strength Index (RSI)
- USAU 60.77
- TPST 41.95
- Support Level
- USAU $5.76
- TPST $0.92
- Resistance Level
- USAU $6.10
- TPST $1.59
- Average True Range (ATR)
- USAU 0.19
- TPST 0.17
- MACD
- USAU 0.02
- TPST -0.02
- Stochastic Oscillator
- USAU 84.85
- TPST 34.33
About USAU U.S. Gold Corp.
U.S. Gold Corp is an exploration and development company that owns certain mining leases and other mineral rights comprising the CK Gold Project in Wyoming, the Keystone Project in Nevada, and the Challis Gold Project in Idaho.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.